Neuroprotective therapies: Preclinical reproducibility is only part of the problem.
Where this comes from
- Record sourced from PubMed, PMID 26246165.
- Also identified by DOI 10.1126/scitranslmed.aac9412.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Among the many unknowns in the translational path to developing drugs for acute stroke, addressing the reproducibility of preclinical data is only one piece of a multifaceted and incomplete puzzle (Llovera et al., this issue).
Medical subject headings
- Drug Evaluation, Preclinical
- Neuroprotection
- Neuroprotective Agents
- Stroke